JPS643128A - Bifunctional antibody structure and selective breakage of cell population - Google Patents

Bifunctional antibody structure and selective breakage of cell population

Info

Publication number
JPS643128A
JPS643128A JP63137599A JP13759988A JPS643128A JP S643128 A JPS643128 A JP S643128A JP 63137599 A JP63137599 A JP 63137599A JP 13759988 A JP13759988 A JP 13759988A JP S643128 A JPS643128 A JP S643128A
Authority
JP
Japan
Prior art keywords
antibody
specific
target cell
bound
antibody structure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP63137599A
Other languages
English (en)
Other versions
JPH013128A (ja
Inventor
Stuart F Schlossman
Charles F Scott Jr
John M Lambert
Walter A Blattler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of JPS643128A publication Critical patent/JPS643128A/ja
Publication of JPH013128A publication Critical patent/JPH013128A/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP63-137599A 1987-06-10 1988-06-06 二官能性抗体構造体及び細胞集団を選択的に破壊する方法 Pending JPH013128A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6020587A 1987-06-10 1987-06-10
US060205 1987-06-10

Publications (2)

Publication Number Publication Date
JPS643128A true JPS643128A (en) 1989-01-06
JPH013128A JPH013128A (ja) 1989-01-06

Family

ID=

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005518431A (ja) * 2002-02-01 2005-06-23 アボット・ラボラトリーズ 高分子コンジュゲート及びその製造方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005518431A (ja) * 2002-02-01 2005-06-23 アボット・ラボラトリーズ 高分子コンジュゲート及びその製造方法
JP2009294216A (ja) * 2002-02-01 2009-12-17 Abbott Lab 高分子コンジュゲート及びその製造方法

Also Published As

Publication number Publication date
DE3853740T2 (de) 1995-11-09
EP0294703A2 (en) 1988-12-14
EP0294703A3 (en) 1990-06-27
EP0294703B1 (en) 1995-05-10
DE3853740D1 (de) 1995-06-14
ATE122238T1 (de) 1995-05-15
ES2073394T3 (es) 1995-08-16

Similar Documents

Publication Publication Date Title
EP0096375A3 (en) Device for separating serum from blood sample
GR3014970T3 (en) Antibodies to tnf binding protein i and f (ab) fragments thereof.
AU1898988A (en) Flow injection apparatus for carrying out chemical analyses
IL105541A0 (en) Monoclonal antibodies to gp130 protein,processes for the preparation thereof and pharmaceutical compositions containing the same
FR2618855B1 (fr) Dispositif de recuperation de vapeurs d'essence
GB2121170B (en) Method for eliminating glucose dependent schiff base effect from hemoglobin a1 assay
NZ217339A (en) Immunoassay for progesterone using monoclonal antibodies
NZ221440A (en) Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections
IL62267A0 (en) Labeled antibodies,compositions containing them and methods for the use thereof
DK234785A (da) Immunanalyse for serumantistoffer
DE3867347D1 (de) Fluessigkristallmischung.
AU7473087A (en) Apparatus for immunoassay with antibody or antigen attached to walls
FR2564394B1 (fr) Dispositif parfumeur, notamment pour automobiles
EP0307149A3 (en) Solid phase immunoassay for an antibody and biological constructions for use therein
EP0109434A4 (en) IN VITRO DIAGNOSTICS METHODS USING MONOCLONAL ANTIBODIES AGAINST PROTEINS OF CONNECTIVE TISSUES.
AU2420888A (en) Immunoassay for antibodies binding platelets
FI880954A7 (fi) Seos ja menetelmä immunologista kastrointia varten.
AU8944291A (en) Immunoassay for the determination of anti-hiv antibodies in human samples
IL77990A (en) Monoclonal anti-alpha-amylase antibody,process for obtaining the same and pharmaceutical compositions containing the same
DK160779C (da) Indretning, der navnlig er anvendelig til pyrolyse af faste eller vaeskeformige proever, der er udtaget i lille maengde
IT209873Z2 (it) Dispositivo circuitale per il rilevamento dell'assetto di veicoli.
FR2634063B1 (fr) Interface microsonde laser pour spectrometre de masse
IL86710A0 (en) Polypeptide receptor for interleukin-2,antibodies against this polypeptide and pharmaceutical compositions containing the same
WO1987007302A3 (en) MONOCLONAL ANTIBODIES TO HUMAN LYMPHOCYTE IgE RECEPTORS, HYBRIDOMAS PRODUCING SUCH ANTIBODIES, AND KITS FOR USING SUCH ANTIBODIES
IT1191288B (it) Sistema di telecomunicazione via satellite per terminali monolocali multiservizi